Published by
The Street
The Street
By Martin Baccardax Moderna said it now sees sales of Spikevax rising to $19 billion this year, with additional signed options of approximately $3 billion. Moderna (MRNA) – Get Moderna, Inc. Report posted must stronger-than-expected fourth quarter earnings Thursday, while boosting its full-year sales forecast for Covid vaccine sales, and unveiled a new $3 billion share repurchase plan. Moderna posted diluted GAAP earnings of $11.29 per share for the three months ending in December, up from a loss of 69 cents per share loss for the same period last year and well ahead of the Street consensus fo…